Skip to main content
bioMérieux logo

bioMérieux — Investor Relations & Filings

Ticker · BIM ISIN · FR0013280286 LEI · 549300AK8Y0LBIQ4T071 PA Manufacturing
Open in API
Filings indexed 414 across all filing types
Latest filing 2025-01-13 M&A Activity
Country FR France
Listing PA BIM

About bioMérieux

https://www.biomerieux.com/

bioMérieux is a global leader in the field of in vitro diagnostics, providing solutions that determine the source of disease and contamination. The company develops and manufactures diagnostic systems, reagents, and software for both clinical and industrial applications. In the clinical sector, its products are used for diagnosing infectious diseases, managing sepsis, combating antimicrobial resistance, and supporting cancer screening and cardiovascular emergencies. For industrial markets, bioMérieux offers microbiological control solutions to ensure the safety and quality of agri-food, pharmaceutical, and cosmetic products. These technologies provide rapid and reliable data to help healthcare professionals and industrial quality control managers make critical decisions that improve patient outcomes and ensure consumer safety.

Recent filings

Filing Released Lang Actions
bioMérieux renforce sa présence sur le marché du diagnostic délocalisé (« Point of Care ») avec l'acquisition de SpinChip Diagnostics, une start-up spécialisée dans les tests immunoessais au plus près
M&A Activity Classification · 95% confidence The document announces that bioMérieux has entered into an agreement to acquire SpinChip Diagnostics ASA, detailing the strategic rationale, financial terms (€138 million enterprise value), and expected impact on future growth. This is a significant corporate action related to financing, M&A, and capital structure. Since the document is a formal press release announcing the acquisition (a takeover/merger activity), the most appropriate classification is Transaction in Own Shares (POS) if it involved share issuance/repurchase, or M&A Activity (TAR) if it is a general acquisition announcement. Given the explicit mention of 'acquisition' and the nature of the transaction, TAR (M&A Activity) is the primary fit, although CAP (Capital/Financing Update) is also relevant due to the financing aspect. However, TAR specifically covers merger proposals or takeover bids, which an acquisition falls under. The document is not a standard regulatory filing like 10-K or IR, nor is it a short announcement of a report (RPA/RNS). It is a detailed press release about a strategic transaction.
2025-01-13 French
Contrat de liquidité bioMérieux au titre du 2e semestre 2024
Net Asset Value Classification · 95% confidence The document is titled "Bilan semestriel du contrat de liquidité BIOMERIEUX" (Semi-annual balance sheet of the liquidity contract) and reports on the status of a liquidity contract (market making agreement) as of December 31, 2024, comparing it to the previous semi-annual balance (June 30, 2024). It details the number of shares and cash held under this agreement and lists transactions (purchases and sales) during the period. This type of regular disclosure regarding market making activities or share stabilization is a specific regulatory requirement, often related to capital management or market transparency. It is not a full annual report (10-K), an earnings release (ER), or a general investor presentation (IP). It most closely aligns with updates concerning capital structure or financing activities, but given the specific nature of reporting on a liquidity contract, it fits best under Capital/Financing Update (CAP) or potentially a specialized regulatory filing. Since it details the status of a formal agreement designed to support share price/liquidity, CAP is the most appropriate fit among the provided options, as it relates directly to capital management mechanisms. It is a specific report, not an announcement of a report.
2025-01-07 French
Décembre 2024 - Déclaration sur le nombre d'actions composant le capital social et sur le nombre de droits de vote correspondant
Declaration of Voting Results & Voting Rights Announcements Classification · 100% confidence The document is titled "Informations mensuelles relatives au nombre total de droits de vote et d'actions prévues par l'article L. 233-8 II du code de commerce et l'article 223-16 du règlement général de l'Autorité des marchés financiers". This explicitly indicates a monthly disclosure regarding the total number of voting rights and shares, as mandated by French commercial code and AMF regulations. This type of filing, which reports on share capital structure and voting rights, is most closely aligned with the general category of regulatory announcements or specific capital structure updates. Given the options, it is a specific regulatory disclosure concerning share capital and voting rights. While it relates to shares (SHA), the specific nature of reporting total voting rights monthly often falls under general regulatory reporting or specific capital disclosures. Since it is a mandatory, periodic disclosure about the total number of shares and voting rights, it fits best under a general regulatory filing or a specific capital/share announcement. Because it is a formal, mandated disclosure of share structure data, and not a general announcement of a transaction (POS) or a general capital change (SHA), it is best classified as a Regulatory Filing (RNS) as it is a specific regulatory report mandated by the AMF, or potentially SHA if interpreted broadly. However, given the context of mandatory monthly reporting of voting rights, RNS (Regulatory Filings - general fallback for specific regulatory disclosures) is appropriate, though SHA (Share Issue/Capital Change) is also relevant. Since the core content is the official count of shares and voting rights, and it's a recurring regulatory requirement, RNS is the safest general regulatory classification if a more specific one isn't available. Let's re-evaluate: This is a mandatory disclosure of the total number of shares and voting rights, which is a fundamental aspect of capital structure reporting. SHA covers 'Share Issue/Capital Change'. This is a report *on* the current capital structure, not necessarily an *issue* or *change*. Therefore, RNS (Regulatory Filings) is the most appropriate general category for this specific, mandated regulatory data report that doesn't fit the other specific categories like DIV, POS, or SHA (which implies a transaction/change).
2025-01-07 French
BIOFIRE® FILMARRAY® Tropical Fever Panel, a syndromic PCR test targeting causes of tropical fever infections, receives U.S. FDA Special 510(k) clearance
Regulatory Filings Classification · 100% confidence The document is a press release dated December 9th, 2024, announcing that bioMérieux's BIOFIRE® FILMARRAY® Tropical Fever Panel received U.S. FDA Special 510(k) clearance. It details the product, its benefits, quotes executives, and mentions future commercial launch plans and regulatory submissions (CE-marking). This type of announcement, which communicates a significant corporate event or regulatory milestone rather than providing periodic financial results (like 10-K or ER) or detailed management analysis (like MDA), fits best under the general category for regulatory or corporate news announcements. Since it is not a standard financial report, a management discussion, an earnings release, or a specific filing like a DEF 14A or DIRS, the most appropriate classification is Regulatory Filings (RNS), which serves as a broad category for important corporate news releases that don't fit elsewhere.
2024-12-09 English
BIOFIRE® FILMARRAY® Tropical Fever Panel, un test PCR pour détecter l’origine des fièvres tropicales, obtient l’autorisation spéciale 510(k) de la FDA américaine
Regulatory Filings Classification · 95% confidence The document is a press release dated December 9, 2024, announcing that bioMérieux's BIOFIRE® FILMARRAY® Tropical Fever Panel received 510(k) clearance from the US FDA. This type of announcement, detailing a regulatory approval or a significant business development (like a product launch/clearance) that is not a full financial report (10-K, IR, ER) or a proxy/shareholder vote material, typically falls under general regulatory announcements or news releases. Since it is a specific announcement about regulatory clearance (FDA 510(k)) and product commercialization plans, it is best classified as a general Regulatory Filing (RNS) or potentially an Earnings Release (ER) if it were tied to quarterly results, but here it is a standalone product/regulatory news item. Given the options, RNS serves as the best fit for a specific, non-financial regulatory milestone announcement that isn't a core financial report or a management change.
2024-12-09 French
Novembre 2024 - Déclaration sur le nombre d'actions composant le capital social et sur le nombre de droits de vote correspondant
Declaration of Voting Results & Voting Rights Announcements Classification · 100% confidence The document is titled "Informations mensuelles relatives au nombre total de droits de vote et d'actions prévues par l'article L. 233-8 II du code de commerce et l'article 223-16 du règlement général de l'Autorité des marchés financiers". This explicitly indicates a monthly disclosure regarding the total number of voting rights and shares, mandated by French commercial code and AMF regulations. This type of filing, which reports on share capital structure and voting rights, is most closely aligned with the general category of regulatory announcements or specific capital structure updates. Given the options, it is a specific regulatory disclosure about share capital/voting rights, which is not explicitly covered by DVA (Voting Results) or SHA (Share Issue). Since it is a mandatory, periodic disclosure of share structure information, it fits best under the general 'Regulatory Filings' (RNS) as a specific regulatory notice, although it contains elements related to capital structure. However, looking closely at the definitions, none perfectly match a 'Monthly Voting Rights Disclosure'. DVA is for voting results, SHA is for new issues/splits. This is a routine disclosure of the current share count and voting rights. In the context of standard SEC/global filings, this is often part of a larger filing or a specific notice. Given the French regulatory context and the nature of the data (total shares/votes), it is a regulatory filing. Since it is not a dividend announcement (DIV), director dealing (DIRS), or a major shareholding change (MRQ), RNS (Regulatory Filings) is the most appropriate fallback for a specific, non-standard regulatory notice.
2024-12-05 French

Browse filings by year

10 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.